OSELTAMIVIR AS ANTIVIRAL THERAPY OF INFLUENZA A(H1N1)pdm09 IN CHILDREN AND ADULTS

In this article are presented the results of comparative of experimental (on cell cultures) study of the influenza virus strains sensitivity to neuraminidase  inhibitor — Oseltamivir and blocker of M-canal — Rimantadin аnd the results of study effectiveness of the inclusion in the complex therapy of 331 hospitalized patients (children and adults) rapy of А(Н1N1)pdm09 antiviral drug — inhibitor of neuraminidase Oseltamivir that occurred during the epidemic seasons 2009—2010 and 2015—2016  in terms of observational clinical studies.  It is shown that this drug, can be successfully used in the treatment of children and adults with influenza А(Н1N1)pdm09 during 8—9 years after beginning of pandemic cycle.

1. Kiselev O.I., Tsybalova L.M., Pokrovsky V.I. [Influenza: Epidemiology, diagnosis, treatment, prevention]. — M., 2012. — 493 p. (In Russ.)

2. Pan C., Cheung B., Tan S. et al. Genomic signature and mutation trend analysis of pandemic (H1N1)2009 influenza A virus // PLOS one. 2010. Vol. 5(3). Р. 9549.

3. Lee E.H., Wu C., Lee E.U. et al. Fatalities associated with the 2009 H1N1 influenza A virus in New York City // Clinical Infectious Diseases. 2010. Vol. 50 (11). P. 1498—1504.

4. Results of pandemic influenza 2009/2011: antiviral therapy and treatment strategy (2nd edition revised)] / Ed. Pokrovsky V.I., Kiselev O.I., Maleev V.V., Tsybalova L.M. — SPb-M, 2012. — 187 p. (In Russ.)

5. B. Cao, X-W. Li, Y. Mao [et al.] Clinical features of the initial cases of 2009 pandemic influenza A (HlNl) virus infection in China // N Engl J Med. 2009. Vol. 361. P. 2507—2517.

6. WHO. Clinical management of human infection with pandemic influenza (H1N1) 2009: Revised guidance. 2009. Nov. P.1 — 19.

7. Donaldson L.J., Rutter P.D., llis B.M et al. Mortality from pandemic A/H1N1 2009 influenza in England: public health surveillance study // BMJ. 2009. Vol. 339. P.b5213.

8. Ward P. et all. Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic // J. Antimicro Chemother 2005; — 55(Suppl 1): Р.15—21.

9. Kolbin A.S., Ivanyuk A.B., Harchev A.V., Shemyakinа T.V., Golikova E.V. [Oseltamivir in pediatric patients (world experience of application)] // Pediatric Pharmacology. 2008. T. 5, №6. S.16—21. (In Russ.)

10. Iain Stephenson et all Neuraminidase Inhibitor Resistance after Oseltamivir Treatment of Acute Influenza A and B in Children // Clinical Infectious Diseases. 2009; 48: Р. 389—396.

11. Afanasyeva O.I., Golovachevа E.G., Voloshchuk L.V., Osidak L.V. et al. [Neuraminidase inhibitor in the treatment of influenza infection] // Children Infection (Detskie Infekcii). 2010. Т.9. №3. С. 35—41. (In Russ.)

12. Potier M., Mameli L., Belislem M., Dallaire L., Melanxon S.B. Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl--D-N-acetylneuraminate) substrate // Anal. Biochem. 1979. 94:287—296.

13. Sominina A.A., Bannikov A.I., Zarubaev V.V., Pisareva M.M. [Laboratory diagnosis of acute respiratory and other viral infections] / Influenza and other respiratory infections: epidemiology, prophylaxis, diagnostics and treatment: ed. O.I. Kiselev. — SPb, 2003:70—91. (In Russ.)

14. A Weekly influenza surveillance Report Prepared by the influenza Division / CDC.2015—2016 Influenza Season —Week 10, ending March, 12, 2016.

15. Golovacheva E.G. [Conceptually-diagnostic patterns of immune response to the flu, and immunotherapy in the treatment of vaccine]: Author. diss. MD ... — St. Petersburg, 2015. 32 p. (In Russ.)

16. Garg S., Fry A.M., Patton M., Fiore A.E., Finelli L. Antiviral treatment of influenza in children // Pediatr Infect Dis J. 2012. Feb; 31(2). P. 43—51.